In breast and prostate cancer, EZH2 drives transcriptional activation by interacting with NF-κB [74] and the androgen receptor [60], respectively, and recent findings suggest that EZH2-cMYC complexes co-activate joint gene signatures, thus promoting acute leukemia [73]. This evidence concerns the gene AR and prostate carcinoma.